Enquirer Consulting Group

Reachable Buyer Map

Prepared for John Cunningham · QPharma · September 2026
Here is the map Katie promised. Your own site sets the boundaries for it: you serve pharmaceutical, biotech, medical device and manufacturing companies, with sampling, distribution, compliance and clinician engagement. So this page takes the US companies that can actually buy those lines, splits them into the groups that behave differently, and for each one shows who owns the decision and roughly how many organizations exist. It maps the market around QPharma, not QPharma. One group has no honest public count and the page says so rather than showing you a number. There is nothing to buy at the end of it.
Where the decision sits
Six rows. Every number counts companies, not sites and not people, unless a row says otherwise. These rows deliberately overlap, because one company can register as a drug maker, report clinician payments and relabel product all at once. They are groups of buying behavior, not a sum, and they should never be added together.
Drug manufacturers registered in the United States
The core of your market and the row where every one of your lines applies at once, from sampling through distribution licensing to spend reporting. The split that matters inside it is not size but whether the company runs its own field force. A company with representatives calling on clinicians has a sampling and licensing problem every quarter. A company that sells entirely through partners has neither, and no register will tell you which is which.
Who decides: the commercial operations or sales operations lead, who owns what the field force can physically hand over and is measured on rep productivity.
Who blocks it: regulatory and quality, because anything that touches a sample has to survive their process before commercial gets a say.
About 3,500
companies, across about 5,300 registered US sites. Company count is distinct registered firm names, so a group registering several plants is counted once.
Companies that reported payments to US clinicians last year
The sharpest row on this page, because membership is self declared, published by name and refreshed every year. A company only appears here if it gave something of value to a clinician and had to say so. That is the same population that has a transparency reporting burden, a license validation burden and, almost always, samples in the field. It is the one segment you never have to guess at.
Who decides: the compliance or transparency owner, usually jointly with commercial, because the obligation is legal and commercial owns the resourcing.
What they ask first: what happens at audit, not what happens on a good day.
More than 1,700
organizations recorded at least one payment to a US clinician in the 2025 reporting year. This population is manufacturers and group purchasing organizations together, not manufacturers alone, and an organization that filed a zero payment return for the year would not appear in it.
Device manufacturers
A near neighbor of the drug row with a different rhythm. Device field teams carry demonstration and evaluation product rather than samples, the clinician relationship runs through the procedure rather than the prescription, and engagement with key opinion leaders tends to be heavier and earlier because adoption follows the surgeon or the specialist. Your industries page already names this segment, so it is scoped in rather than stretched to.
Who decides: the commercial lead or the vice president of sales, closer to the revenue number than in the drug row.
About 4,900
companies, across about 5,300 registered US manufacturing sites.
Specification developers, the design and market businesses
The quiet row, and the most interesting one. These are companies that develop the product but manufacture it nowhere themselves, which means the whole business is design, brand and commercial. They tend to run lean teams, they own no infrastructure to fall back on, and they are the least likely of any row here to be standing at the large congresses. Everything you sell that is a service rather than a warehouse fits this group, and almost nobody is selling to them deliberately.
Who decides: often the founder or the single commercial lead, directly, in one conversation rather than through a committee.
About 3,400
companies registered as developing specifications but not manufacturing at that facility.
Repackagers, relabelers and contract manufacturers
Two adjacent groups with one thing in common: they handle other people's product, so distribution licensing, validation and quality auditing are burdens they already carry. They do not buy clinician engagement, so this is a narrower conversation than the rows above and should be weighted as such in your time rather than treated as core market. Worth knowing it exists before someone counts it inside the total.
Who decides: the business development lead for new work, but quality and operations own the standard they have to meet.
About 2,650
repackager or relabeler companies, plus about 2,050 contract manufacturers. Many appear in the manufacturer row too.
Pre commercial companies preparing a first US launch
Strategically your best row and the one this page refuses to put a number on. A company preparing its first launch has no sampling operation, no distribution licensing and no reporting history, so it buys the whole stack at once rather than replacing an incumbent. The problem is that no public register enumerates it: a company is not listed as pre commercial anywhere, and the moment it registers it looks identical to an established manufacturer. Any number you are shown for this segment by anyone has been estimated, not counted.
Who decides: the first commercial hire, often a chief commercial officer brought in ahead of the launch, which is the same seat that buys the most and is hardest to find on a list.
No honest public count
This row is built by hand from launch signals, not bought. It is named here because leaving it out would make the map look more complete than it is.
The device side, by what they actually do
The same registration file, split by the operation each site declares. A site can declare more than one, so these rows overlap by design and do not sum to the total.
Declared operationCompaniesRegistered sites
Manufacturer4,9265,267
Specification developer3,4423,565
Repackager or relabeler2,6582,769
Complaint file establishment2,2192,289
Contract manufacturer2,0622,202
US manufacturer, export only491573
Remanufacturer201208
Contract sterilizer114154

Where the openings are

1
One of your rows publishes itself every year, and it is the row that has to buy. More than 1,700 organizations declare by name that they gave something of value to a US clinician in the last reporting year. That is a named, dated, annually refreshed list of companies with a transparency obligation, sitting in public, free. Nobody has to wait for that segment to walk past a stand at a congress. The work is not finding them, it is deciding which two hundred of them are worth a named approach and who inside each one owns the problem.
2
The design and market segment is the one nobody is working. About 3,400 companies develop product and manufacture none of it, which means no infrastructure, lean commercial teams and a founder or single commercial lead who can say yes without a committee. They are also the least likely to be at the large events, which is precisely why they stay unworked: a demand motion built on congresses and content cannot reach a company that does not attend and does not search. Reaching them is an outbound problem, not a marketing one.
3
The companies that sit in three rows at once are the whole product line in one account. These rows overlap on purpose. A company that manufactures, reports clinician payments and relabels is buying sampling, licensing and transparency from somebody already, probably from three different somebodies. That overlap is not in any register and it is not hard to build, but it has to be built, because it is the difference between selling one line into many accounts and selling the platform into the accounts that need all of it. It is the single highest value list on this page.
Built from public federal registration files and the federal database of reported payments to clinicians, all pulled in full on 21 September 2026. Counts are companies unless a row says sites, and a company count is distinct registered firm names, so a group registering several plants is counted once. Rows overlap by design and must not be added together. Counts are banded deliberately. A registration proves enumeration only, never size, quality or activity, and a segment with no credible public number says so here rather than showing one.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com